Perioperative allergic conjunctivitis increases the speed of lymphatic ingrowth

Article

The natural immunity to allogeneic corneal tissue is stronger in allergic conjunctivitis and is linked to lymphatic ingrowth.

An investigation featured in the British Journal of Ophthalmology has demonstrated that the natural immunity to allogeneic corneal tissue is stronger in allergic conjunctivitis and is linked to lymphatic ingrowth.

A team led by Dr T. H. Flynn, Department of Ocular Immunology, UCL Institute of Ophthalmology, London, UK, transplanted allogeneic fully MHC-mismatched C57Bl/6 strain donor corneas into naïve A/J mice and A/J mice suffering from active allergic conjunctivitis. Other groups of mice with allergic conjunctivitis were postoperatively administered topical dexamethasone 0.1% twice daily or phosphate-buffered saline.

On day 2 and day 6 the mice were killed and the corneas were examined. This was completed by fluorescent immunohistochemistry using anti-CD11b, anti-F4/80 and anti-Gr-1 antibodies or whole-mount staining with anti-LYVE-1 antibody. The amount of cells infiltrating the cornea and lymphatic ingrowth were compared between the groups.

At day 2 the results presented a significantly high amount of CD11b+ cells and LYVE-1+ vessels in the host cornea. However, there were no differences in naïve and allergic mice in day 6. Topical dexamethasone prevents lymphatic growth and could be a mechanism for topical steroid enhancing graft survival.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.